Breaking News Instant updates and real-time market news.

AXP

American Express

$72.86

-0.02 (-0.03%)

, BAYRY

Bayer

$94.14

0.855 (0.92%)

07:11
11/28/16
11/28
07:11
11/28/16
07:11

Radiological Society of North America to hold a conference

RSNA 2016 is being held in Chicago on November 27-December 2.

AXP

American Express

$72.86

-0.02 (-0.03%)

BAYRY

Bayer

$94.14

0.855 (0.92%)

BTC

Bitcoin

CAJ

Canon

$28.25

0.17 (0.61%)

CERN

Cerner

$50.49

-0.02 (-0.04%)

VAR

Varian Medical

$92.14

0.52 (0.57%)

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 30

    Nov

  • 07

    Dec

AXP American Express
$72.86

-0.02 (-0.03%)

11/18/16
11/18/16
INITIATION
Target $62

Underweight
Discover initiated with an Underweight at Stephens
As previously reported, Stephens analyst Vincent Caintic started Discover (DFS) with an Underweight rating and $62 price target, citing shrinking margins as American Express (AXP) ramps up rewards to maintain share, credit costs normalizing higher likely making Discover's shares range bound, and personal lending competition. The analyst also started American Express with an Underweight rating.
11/18/16
11/18/16
INITIATION
Target $40

Overweight
Synchrony initiated with an Overweight at Stephens
As previously reported, Stephens analyst Vincent Caintic started Synchrony (SYF) with an Overweight rating and $40 price target, citing $5B excess capital that allows Synchrony to buy back 20% of company once capital return is deregulated, industry retail share weakness, and revenue growth. The analyst also started American Express (AXP) and Discover (DFS) with an Underweight rating.
11/18/16
11/18/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cisco (CSCO) coverage resumed with a Hold at Stifel. 2. UPS (UPS) was initiated with an Outperform at BMO Capital while the firm initiated FedEx (FDX) with a Market Perform. 3. Synchrony (SYF) was initiated with an Overweight at Stephens. The firm also initiated American Express (AXP) and Discover (DFS) with an Underweight. 4. American Airlines (AAL), Delta Air Lines (DAL), Southwest (LUV) and Allegiant Travel (ALGT) were initiated with a Buy at Citi while the firm initiated JetBlue (JBLU), United Continental (UAL), Alaska Air (ALK), and Hawaiian Holdings (HA) with a Neutral. 5. Juniper (JNPR) coverage resumed at Stifel. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/18/16
11/18/16
INITIATION
Target $65

Underweight
American Express initiated with an Underweight at Stephens
As previously reported, Stephens analyst started American Express (AXP) with an Underweight rating and $65 price target, citing rising rates, shrinking markets as American Express ramps up rewards to maintain share, and the risk to 2017 EPS guidance. The analyst expects competition from bank peers, such as JPMorgan (JPM) and Citi (C), to continue to pressure American Express' earnings.
BAYRY Bayer
$94.14

0.855 (0.92%)

09/26/16
BERN
09/26/16
UPGRADE
BERN
Market Perform
Monsanto upgraded on acquisition at Bernstein
As noted earlier, Bernstein upgraded Monsanto (MON) to Market Perform from Underperform. Analyst Jonas Oxgaard upgraded the stock after Bayer (BAYRY) agreed to buy Monsanto. However, he warned that "it's too early to tell" whether regulators will approve the deal, and he says that the risk is "skewed to the downside in the near-term." He recommends that investors avoid the stock for 6-9 months. Target to $105 from $90.
09/15/16
PIPR
09/15/16
NO CHANGE
Target $128
PIPR
Overweight
Piper has confidence in closing of Monsanto, Bayer merger
Piper Jaffray analyst Brett Wong raised his price target for Monsanto (MON) to $128 citing the takeover price paid by Bayer (BAYRY). The analyst views the offer price as lower than expected but has confidence regulatory approval will be granted since there is a minimal crossover between the two companies. He reiterates an Overweight rating on Monsanto.
09/15/16
BERN
09/15/16
NO CHANGE
BERN
Bayer acquisition negative, says Bernstein
After Bayer (BAYRY) agreed to buy Monsanto (MON), Bernstein analyst Jonas Oxgaard says he "continues to have a bearish view" of Monsanto's business, and he thinks that Monsanto's price exceeded the company's true value by about 60%. The analyst adds that the genetically modified products that Monsanto is developing "are not expected to command outsized premiums," while genetically modified seeds have nearly fully penetrated most of the Americas. He keeps an Underperform rating on Monsanto and an Outperform rating on Bayer.
09/21/16
JPMS
09/21/16
UPGRADE
Target $128
JPMS
Overweight
Monsanto upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Jeffrey Zekauskas upgraded Monsanto (MON) to Overweight saying the risk in the shares is "less than what the market assumes." The analyst believes downside risk should the takeover by Bayer (BAYRY) fail is around $100 per share. He notes that Monsanto shareholders would receive $128 per share should the acquisition close. Zekauskas raised his price target for Monsanto to $128 from $100.
BTC Bitcoin

CAJ Canon
$28.25

0.17 (0.61%)

10/27/16
BOFA
10/27/16
DOWNGRADE
BOFA
Underperform
Canon downgraded to Underperform from Neutral at BofA/Merrill
10/26/16
JPMS
10/26/16
DOWNGRADE
JPMS
Underweight
Canon downgraded to Underweight from Neutral at JPMorgan
11/25/16
LYON
11/25/16
UPGRADE
LYON
Outperform
Canon upgraded to Outperform from Underperform at CLSA
07/15/16
LYON
07/15/16
DOWNGRADE
LYON
Underperform
Canon downgraded to Underperform from Buy at CLSA
CLSA analyst Claudio Aritomi downgraded Canon to Underperform from Buy saying there is a high probability Canon will cut its guidance for FY16 along with 2Q results.
CERN Cerner
$50.49

-0.02 (-0.04%)

11/17/16
KEYB
11/17/16
NO CHANGE
KEYB
Cerner outlook still positive, says KeyBanc
KeyBanc analyst Donald Hooker says that President-elect Trump's victory "creates near-term uncertainty for Cerner's population health businesses." However, the analyst expects the company's revenue cycle businesses to continue to grow by at least 10%. He predicts that the company will exploit the Trump Administration's more favorable stance towards drug development by providing information to life sciences companies. He keeps a $77 price target and an Outperform rating on the shares.
11/10/16
DBAB
11/10/16
DOWNGRADE
DBAB
Hold
Cerner, Allscripts downgraded to Hold on ACA uncertainty at Deutsche Bank
As previously reported, Deutsche Bank analyst George Hill downgraded Cerner (CERN) and Allscripts (MDRX), both to Hold from Buy, citing the "high likelihood" that the Affordable Care Act gets repealed or significantly scaled back following the election of Donald Trump. Given the likely repeal, and uncertainty on what will replace the ACA, Hill sees a less certain outlook for hospital based IT spending. Hill cut his price target on Cerner to $50 from $58 and on Allscripts to $11 from $14.
11/10/16
DBAB
11/10/16
DOWNGRADE
DBAB
Hold
Cerner downgraded to Hold from Buy at Deutsche Bank
11/07/16
BOFA
11/07/16
DOWNGRADE
BOFA
Underperform
Cerner downgraded to Underperform on capex slowdown at BofA/Merrill
As previously reported, BofA/Merrill downgraded Cerner to Underperform from Neutral and lowered its price target to $51 from $61. Analyst Steven Valiquette believes hospital customers are "tightening the belts" further in 2017 given reimbursement challenges and expects the company to see slower growth than in prior years. .
VAR Varian Medical
$92.14

0.52 (0.57%)

01/12/16
BRRR
01/12/16
INITIATION
Target $91
BRRR
Outperform
Varian Medical assumed with an Outperform at Barrington
Barrington analyst Michael Petusky assumed coverage of Varian Medical with an Outperform rating and $91 price target.
04/28/16
BMUR
04/28/16
NO CHANGE
Target $87
BMUR
Buy
Varian Medical price target raised to $87 from $82 at Brean Capital
Brean Capital raised its price target on Varian Medical to $87 from $82 following mixed Q2 results. The firm cited its lowered guidance, which they now see as achievable. Brean Capital reiterated its Buy rating on Varian Medical shares.
07/08/16
BARD
07/08/16
NO CHANGE
Target $84
BARD
Neutral
No change in PFS proposed rates a positive for Varian Medical, says Baird
Baird analyst Jeff Johnson noted that CMS released CY 2017 proposed payment rates under the Physician Fee Schedule and said the flat proposed rate changes for a typical radiation freestanding center next year is a positive for Varian Medical. While the flat proposed rate is in-line with management guidance, will still likely come as a relief for investors, said Johnson, who keeps a Neutral rating and $84 price target on Varian shares.
10/20/16
SBSH
10/20/16
NO CHANGE
SBSH
General Electric takeover of Varian Medical unlikely, says Citi
Citigroup said General Electric (GE) exited the radiation oncology space in the 1990's and since then has had virtually no interest in getting into the treatment side of healthcare versus diagnostics. Further, the firm's analyst said Varian (VAR) is in the midst of spinning off their imaging business, and in theory, would make Varian a much more attractive target for General Electric. However, Citi said a takeover of Varian before the spin closing in December would make no sense by General Electric and reduces the firm's belief in today's speculation.

TODAY'S FREE FLY STORIES

BRO

Brown & Brown

$52.25

-0.25 (-0.48%)

17:05
01/22/18
01/22
17:05
01/22/18
17:05
Earnings
Brown & Brown reports Q4 EPS 47c, consensus 42c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

EAT

Brinker

$38.39

0.08 (0.21%)

, GS

Goldman Sachs

$261.52

5.4 (2.11%)

17:03
01/22/18
01/22
17:03
01/22/18
17:03
Hot Stocks
Brinker adds James Katzman To Board of Directors »

Brinker (EAT) announces…

EAT

Brinker

$38.39

0.08 (0.21%)

GS

Goldman Sachs

$261.52

5.4 (2.11%)

HSY

Hershey

$109.96

0.59 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 31

    Jan

  • 01

    Feb

CCXI

ChemoCentryx

$8.31

-0.04 (-0.48%)

17:01
01/22/18
01/22
17:01
01/22/18
17:01
Hot Stocks
ChemoCentryx reports 'positive' survival results from CCX872 trial »

ChemoCentryx announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NWHM

New Home Company

$12.89

0.01 (0.08%)

16:58
01/22/18
01/22
16:58
01/22/18
16:58
Syndicate
Breaking Syndicate news story on New Home Company »

New Home Company files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

NWHM

New Home Company

$12.89

0.01 (0.08%)

16:58
01/22/18
01/22
16:58
01/22/18
16:58
Syndicate
Breaking Syndicate news story on New Home Company »

New Home Company files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

TROW

T. Rowe Price

$117.40

0.05 (0.04%)

16:57
01/22/18
01/22
16:57
01/22/18
16:57
Hot Stocks
T. Rowe Price sees FY18 effective tax rate 24%-27% »

On December 22, 2017, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICE

IntercontinentalExchange

$75.83

0.23 (0.30%)

16:45
01/22/18
01/22
16:45
01/22/18
16:45
Hot Stocks
Natixis, NYSE enter licensing agreement »

Natixis Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBIO

Catalyst Biosciences

$21.21

1.72 (8.83%)

16:43
01/22/18
01/22
16:43
01/22/18
16:43
Syndicate
Breaking Syndicate news story on Catalyst Biosciences »

Catalyst Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRET

Investors Real Estate

$5.74

0.03 (0.53%)

16:40
01/22/18
01/22
16:40
01/22/18
16:40
Hot Stocks
Investors Real Estate completes sale of two additional medical office buildings »

IRET completed the sale…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FFIC

Flushing Financial

$28.93

-0.1 (-0.34%)

16:39
01/22/18
01/22
16:39
01/22/18
16:39
Hot Stocks
Flushing Financial announces dividend plans for 2018 »

Flushing Financia, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

JMBA

Jamba

$9.14

-0.01 (-0.11%)

16:37
01/22/18
01/22
16:37
01/22/18
16:37
Syndicate
Jamba 2.1M share Block Trade; price range $8.25-$8.40 »

Morgan Stanley is acting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FULT

Fulton Financial

$18.65

0.1 (0.54%)

16:37
01/22/18
01/22
16:37
01/22/18
16:37
Earnings
Fulton Financial reports Q4 EPS 19c, consensus 28c »

Net interest income for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

AMGN

Amgen

$192.33

3.05 (1.61%)

16:36
01/22/18
01/22
16:36
01/22/18
16:36
Hot Stocks
Amgen: Aimovig met all primary, secondary endpoints in Phase 3b LIBERTY study »

Amgen announced positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 03

    Feb

  • 16

    Feb

  • 08

    Mar

  • 25

    Mar

  • 23

    Apr

  • 30

    Apr

  • 17

    May

  • 28

    May

AMGN

Amgen

$192.33

3.05 (1.61%)

16:34
01/22/18
01/22
16:34
01/22/18
16:34
Hot Stocks
Breaking Hot Stocks news story on Amgen »

Amgen: Aimovig met all…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 03

    Feb

  • 16

    Feb

  • 08

    Mar

  • 25

    Mar

  • 23

    Apr

  • 30

    Apr

  • 17

    May

  • 28

    May

FL

Foot Locker

$50.37

0.16 (0.32%)

16:32
01/22/18
01/22
16:32
01/22/18
16:32
Hot Stocks
Foot Locker makes strategic investment in Carbon38 »

Foot Locker announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPE

EP Energy

$2.48

0.17 (7.36%)

16:32
01/22/18
01/22
16:32
01/22/18
16:32
Hot Stocks
EP Energy sees FY18 $600M-$650M of oil and gas expenditures, »

Sees FY18 81…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$98.06

-0.98 (-0.99%)

16:31
01/22/18
01/22
16:31
01/22/18
16:31
Hot Stocks
Darden names Dave George as COO »

Darden Restaurants…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RAD

Rite Aid

$2.29

-0.02 (-0.87%)

, WBA

Walgreens Boots Alliance

$77.40

0.93 (1.22%)

16:31
01/22/18
01/22
16:31
01/22/18
16:31
Hot Stocks
Rite Aid provides update on sale of assets to Walgreens Boots Alliance »

Rite Aid Corporation…

RAD

Rite Aid

$2.29

-0.02 (-0.87%)

WBA

Walgreens Boots Alliance

$77.40

0.93 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZION

Zions Bancorp

$54.16

0.43 (0.80%)

16:30
01/22/18
01/22
16:30
01/22/18
16:30
Earnings
Zions Bancorp reports Q4 adjusted EPS 80c, consensus 73c »

Harris H. Simmons,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

EPE

EP Energy

$2.48

0.17 (7.36%)

16:30
01/22/18
01/22
16:30
01/22/18
16:30
Hot Stocks
EP Energy reports preliminary FY17 production results of 82,300MBoe/d »

Preliminary FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
01/22/18
01/22
16:30
01/22/18
16:30
Options
Preliminary option volume of 20.3M today »

Preliminary option volume…

RMD

ResMed

$87.51

-1.17 (-1.32%)

16:30
01/22/18
01/22
16:30
01/22/18
16:30
Hot Stocks
Breaking Hot Stocks news story on ResMed »

ResMed up 8.5% to $95.00…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

EMR

Emerson

$73.26

0.12 (0.16%)

16:29
01/22/18
01/22
16:29
01/22/18
16:29
Initiation
Emerson initiated  »

Emerson initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

JUNO

Juno Therapeutics

$86.00

18.19 (26.83%)

, CELG

Celgene

$102.91

0.26 (0.25%)

16:28
01/22/18
01/22
16:28
01/22/18
16:28
Downgrade
Juno Therapeutics, Celgene rating change  »

Juno Therapeutics…

JUNO

Juno Therapeutics

$86.00

18.19 (26.83%)

CELG

Celgene

$102.91

0.26 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

HSGX

Histogenics

16:28
01/22/18
01/22
16:28
01/22/18
16:28
Syndicate
Breaking Syndicate news story on Histogenics »

Histogenics files $50M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.